ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) are part of renin-angiotensin-aldosterone system (RAS) inhibiting agents and considered as one of the first-line medications for the management of a large proportion of patients with hypertension.5,6 However, continued use of ACEI/ARB has become controversial in the setting of COVID-19. This evidence concerns the gene ACE and COVID-19.